Ligand Pharmaceuticals (LGND) Other Operating Expenses (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Other Operating Expenses of $11.4 million in Q1 2026, down 34.22% quarter-over-quarter from $17.3 million in Q4 2025, and down 10.21% year-over-year from $12.7 million in Q1 2025.
Ligand Pharmaceuticals' Other Operating Expenses history runs 16 years deep, the most recent figure standing at $11.4 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 10.21% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $52.2 million (up 3.66% YoY), while the FY2023 annual figure was $2.1 million, changed N/A from the prior year.
- Other Operating Expenses came in at $11.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $17.3 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $37.7 million in Q2 2024 to a low of $2.1 million in Q3 2023.
- A 5-year average of $13.8 million and a median of $12.3 million in 2023 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses surged 268.87% in 2024 and plunged 66.96% in 2025, its largest moves.
- Ligand Pharmaceuticals' Other Operating Expenses stood at $13.3 million in 2022, then plunged by 84.03% to $2.1 million in 2023, then jumped by 1675.29% to $37.7 million in 2024, then slumped by 54.1% to $17.3 million in 2025, then plunged by 34.22% to $11.4 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $11.4 million, $17.3 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.37 Mn |
| Dec 31, 2025 | 17.29 Mn |
| Sep 30, 2025 | 11.07 Mn |
| Jun 30, 2025 | 12.44 Mn |
| Mar 31, 2025 | 12.66 Mn |
| Jun 30, 2024 | 37.65 Mn |
| Mar 31, 2024 | 11.07 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 10.21 Mn |
| Mar 31, 2023 | 12.26 Mn |
| Mar 31, 2022 | 13.28 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 34.10 Mn |
| Mar 31, 2021 | 17.01 Mn |
| Dec 31, 2020 | -600,000.00 |
| Mar 31, 2019 | 812.80 Mn |
| Dec 31, 2017 | 10.06 Mn |
| Sep 30, 2017 | 10.51 Mn |
| Jun 30, 2017 | 8.50 Mn |
| Mar 31, 2017 | 3.12 Mn |
| Dec 31, 2016 | 5.63 Mn |
| Sep 30, 2016 | 3.71 Mn |
| Jun 30, 2016 | 3.03 Mn |
| Mar 31, 2016 | 3.24 Mn |
| Dec 31, 2015 | 2.24 Mn |
| Sep 30, 2015 | 1.25 Mn |
| Jun 30, 2015 | 3.19 Mn |
| Mar 31, 2015 | 1.67 Mn |
| Dec 31, 2014 | 6.38 Mn |
| Sep 30, 2014 | 1.50 Mn |
| Jun 30, 2014 | 1.19 Mn |
| Mar 31, 2014 | 2.45 Mn |
| Dec 31, 2013 | 1.32 Mn |
| Sep 30, 2013 | 2.54 Mn |
| Jun 30, 2013 | 1.69 Mn |
| Mar 31, 2013 | 663,000.00 |
| Dec 31, 2012 | 2.33 Mn |
| Sep 30, 2012 | 683,000.00 |
| Jun 30, 2012 | 435,000.00 |
| Mar 31, 2012 | 242,000.00 |
| Dec 31, 2011 | 2.60 Mn |
| Sep 30, 2011 | 2.98 Mn |
| Jun 30, 2011 | 1.61 Mn |
| Mar 31, 2011 | 374,000.00 |
| Dec 31, 2010 | 3.71 Mn |
| Sep 30, 2010 | 15.89 Mn |